Company: PSTV
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047698
Chunk: 155

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 155
---
 receivable

    (571
    )

    —

    Other assets

    218

    2,397

    Accounts payable and accrued expenses

    4,702

    (3,677
    )

    Change in operating lease liabilities

    (130
    )

    (117
    )

    Deferred grant liability

    (997
    )

    281

    Net cash used in operating activities

    (10,554
    )

    (12,851
    )

    Cash flows used in investing activities:

    Purchases of property and equipment

    (146
    )

    (160
    )

    Purchases of intangible assets

    (545
    )

    —

    Purchases of short-term investments

    (15,590
    )

    —

    Redemption of short-term investments

    12,170

    —

    Net cash used in investing activities

    (4,111
    )

    (160
    )

    Cash flows from financing activities:

    Principal payments of long-term obligations

    (3,996
    )

    (1,608
    )

    Proceeds from credit facility

    3,292

    —

    Proceeds from sale of common stock, warrants and pre-funded warrants, net

    7,265

    —

    Proceeds from sale of common stock, net of offering costs of $0.2 million

    —

    5,527

    Payment of offering costs related to sale of common stock

    —

    (348
    )

    Purchase of treasury stock

    (374
    )

    (126
    )

    Net cash provided by financing activities

    6,187

    3,445

    Net decrease in cash and cash equivalents

    (8,478
    )

    (9,566
    )

    Cash and cash equivalents at beginning of period

    8,554

    18,120

    Cash and cash equivalents at end of period
     
    $
    76

    $
    8,554

    Supplemental disclosure of cash flows information:

    Cash paid during period for:

    Interest
     
    $
    32

    $
    222

    Supplemental schedule of non-cash investing and financing activities:

    Unpaid offering cost
     
    $
    —

    $
    174

    Common stock issued in payment for in process research and development